Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control
Completed
This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC